In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

EyeTech closes $108.5mm Series C placement

Executive Summary

EyeTech Pharmaceuticals Inc. (eye disease drugs) could raise as much as $108.5mm in a two-tranche private placement of Series C preferred stock led by JP Morgan Partners. Other investors were BB Biotech, MPM Capital, Alta Partners, Schroder Ventures, and Merrill Lynch. The first half of the financing is payable immediately; the second $54.2mm is payable on the completion of enrollment of the two pivotal Phase III trials of its lead product, Macugen, for age-related macular degeneration (AMD).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies